- Home
- NKTR vs OPY Comparison
NKTR vs OPY Comparison
Compare NKTR & OPY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NKTR | OPY |
|---|---|---|
| Founded | 1990 | 1881 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 807.8M | 802.2M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | NKTR | OPY |
|---|---|---|
| Price | $69.83 | $86.54 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $122.33 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 56.4K |
| Earning Date | 03-11-2026 | 01-30-2026 |
| Dividend Yield | N/A | ★ 0.82% |
| EPS Growth | N/A | ★ 104.71 |
| EPS | N/A | ★ 13.04 |
| Revenue | $62,600,000.00 | ★ $1,551,510,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.70 |
| Revenue Growth | N/A | ★ 15.40 |
| 52 Week Low | $6.48 | $49.26 |
| 52 Week High | $67.94 | $94.10 |
Technical Indicators
Market Signals| Indicator | NKTR | OPY |
|---|---|---|
| Relative Strength Index (RSI) | 81.50 | 58.15 |
| Support Level | $34.47 | $83.04 |
| Resistance Level | $39.43 | $94.10 |
| Average True Range (ATR) | 3.96 | 3.75 |
| MACD | 4.04 | 0.25 |
| Stochastic Oscillator | 95.36 | 61.11 |
Price Performance
Historical ComparisonAbout NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
About OPY Oppenheimer Holdings Inc. (DE)
Oppenheimer Holdings Inc conducts activities in the securities industry. The company is involved in retail securities brokerage, investment banking (both corporate and public finance), institutional sales and trading, market-making, research, trust services, and investment advisory and asset management services. The company has two segments: Wealth Management, and Capital Markets. IT generates maximum revenue from Wealth Management Segment which includes commissions and fee income earned on assets under management (AUM), net interest earnings on client margin loans and cash balances, fees from money market funds, custodian fees and other activities. The company generates the majority of its revenue from the Americas, with the rest from Europe, the Middle East, and Asia.